EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency, a new class of biomarker cell ...
On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026Planned UK trial to ...
Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent ...
How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of ...
Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...
Abzena, a CDMO, said it has expanded its early- and late-phase analytical capabilities to now include GMP cell-based potency assays at their Cambridge, U.K., and San Diego, CA, development and ...
CAR T-cell therapy is considered a revolution in cancer treatment, offering several advantages over traditional chemotherapy. It provides precise targeting of specific cancer types, uses the patient's ...
Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback